Td. Richardson et al., HALF-LIFE DETERMINATION OF SERUM-FREE PROSTATE-SPECIFIC ANTIGEN FOLLOWING RADICAL RETROPUBIC PROSTATECTOMY, Urology, 48(6A), 1996, pp. 40-44
Objectives, Prostate-specific antigen (PSA) continues to be the the mo
st clinically useful tumor marker for prostate cancer. Recently, sever
al molecular forms of PSA have been detected and characterized. These
specific forms, including free PSA and PSA complexed to alpha(1)-antic
hymotrypsin can be measured and their proportions determined. In doing
so, the sensitivity of PSA as a tumor marker can be maintained while
the specificity is improved. In order to maximize the clinical utility
of free PSA, the half-life and elimination kinetics of free PSA from
the serum were determined. Methods, Twenty-five patients, ages 43-74 y
ears (mean 60 years) with biopsy proven, organ-confined adenocarcinoma
of the prostate who underwent anatomic radical retropubic prostatecto
my, were identified. For each patient, venous blood samples were obtai
ned preoperatively, and at 60-minute intervals beginning hour after th
e prostate was removed. The specimens were handled and stored in a con
sistent fashion. Using the AxSYM(R) immunoassay analyzer (Abbott Diagn
ostics, Abbott Park, IL), the serum free PSA values were determined an
d plotted as a function of time for each patient. From the 25 individu
al elimination curves that were generated, the half-life of serum free
PSA was determined. Results. The mean half-life of serum free PSA was
110 minutes +/- 18.6 minutes (SD), Analysis of the individual and cum
ulative elimination curves indicates that the elimination of free PSA
from the serum following radical prostatectomy follows a biphasic patt
ern. Conclusions, Unlike PSA, which has a half life of 2-3 days, the h
alf-life of serum free PSA is 110 minutes (1.83 hours). This short hal
f-life may have significant implications for the use of percentage of
free PSA as a clinically useful tool in distinguishing patients with e
arly, curable prostate cancer from men with benign prostatic hyperplas
ia (BPH) only. Copyright 1996 by Elsevier Science Inc.